摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

倍他米松丙酸酪酸盐 | 5534-02-1

中文名称
倍他米松丙酸酪酸盐
中文别名
丙丁倍他米松
英文名称
(+)-9-fluoro-11β,17,21-trihydroxy-16β-methylpregna-1,4-diene-3,20-dione 17-butyrate 21-propionate
英文别名
betamethasone butyrate propionate;Antebate;BBP;[(8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-17-(2-propanoyloxyacetyl)-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] butanoate
倍他米松丙酸酪酸盐化学式
CAS
5534-02-1
化学式
C29H39FO7
mdl
MFCD00865998
分子量
518.623
InChiKey
VXOWJCTXWVWLLC-REGDIAEZSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    approximate 152℃
  • 沸点:
    613.0±55.0 °C(Predicted)
  • 密度:
    1.23±0.1 g/cm3(Predicted)
  • 溶解度:
    可溶于氯仿(轻微)、二恶烷(轻微、超声处理)、甲醇(轻微)

计算性质

  • 辛醇/水分配系数(LogP):
    3.4
  • 重原子数:
    37
  • 可旋转键数:
    9
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.724
  • 拓扑面积:
    107
  • 氢给体数:
    1
  • 氢受体数:
    8

安全信息

  • 储存条件:
    | 2-8℃ |

SDS

SDS:762857dd43f93433035bdfd35f80bff4
查看

制备方法与用途

生物活性方面,Betamethasone-17-butyrate-21-propionate 是一种具有潜在研究价值的局部皮质类固醇,适用于炎性皮肤疾病的治疗。

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
    倍他米松17-丁酸酯 9α-fluoro-11β,17α,21-trihydroxy-16β-methyl-1,4-pregnadiene-3,20-dione 17-butyrate 5534-14-5 C26H35FO6 462.559
    倍他米松 betamethasone 378-44-9 C22H29FO5 392.468

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS<br/>[FR] DÉRIVÉS DE PYRROLOTRIAZINONE EN TANT QU'INHIBITEURS DES PI3K
    申请人:ALMIRALL SA
    公开号:WO2014060432A1
    公开(公告)日:2014-04-24
    New pyrrolotriazinone derivatives having the chemical structure of formula (I), are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Phosphoinositide 3-Kinases (PI3Ks)
    新的吡咯三唑酮衍生物具有化学结构式(I),公开;以及它们的制备方法,包括它们的药物组合物和它们作为磷脂酰肌醇3-激酶(PI3Ks)抑制剂在治疗中的应用。
  • NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS
    申请人:MUTHUPPALANIAPPAN Meyyappan
    公开号:US20110275603A1
    公开(公告)日:2011-11-10
    The present invention provides dihydroorotate dehydrogenase inhibitors, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of diseases or disorders wherein the inhibition of Dihydroorotate dehydrogenase is known to show beneficial effect.
    本发明提供了脱氢鸟苷酸脱氢酶抑制剂,其制备方法,含有它们的药物组合物以及治疗、预防和/或改善疾病或障碍的方法,其中已知抑制脱氢鸟苷酸脱氢酶具有益处效果。
  • New CRTh2 antagonists
    申请人:Almirall, S.A.
    公开号:EP2548876A1
    公开(公告)日:2013-01-23
    The present invention relates to compounds of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by CRTh2 antagonist activity.
    本发明涉及式(I)的化合物,制备这种化合物的方法以及它们在治疗病理状况或疾病中的应用,该病理状况或疾病容易通过CRTh2拮抗活性得到改善。
  • TROPAN COMPOUND
    申请人:ONO PHARMACEUTICAL CO., LTD.
    公开号:EP1785421A1
    公开(公告)日:2007-05-16
    The conventional anticholinergic drugs for administration through inhalation have been considered to have the possibility of aggravating dysuria associated with prostatic hyperplasia mediated by blood, and it has been demanded that the conventional anticholinergic drugs for administration through inhalation will have to show reduced side effects or adverse ractions. The present invention relates to a compound represented by the general formula (I): (wherein A represents; and R1, R2, R3 and R1 each a hydrogen atom or a substituent; R5 is a substituent; X- is an anion;the symbol: denotes an exo-form or endo-form, or their mixture), its salt or solvation product thereof. They are useful as a prophylactic and/or therapeutic agent with reduced side effects or adverse reactions for the diseases mediated by the muscarinic receptor.
    传统的抗胆碱药物通过吸入给药被认为可能加重与前列腺增生相关的排尿困难,并要求传统的抗胆碱药物通过吸入给药必须显示减少副作用或不良反应。 本发明涉及一种由通式(I)表示的化合物: (其中A代表; 和R1、R2、R3和R1分别是氢原子或取代基; R5是取代基; X-是阴离子;符号: 表示外向型或内向型,或它们的混合物),其盐或溶剂化产物。它们可用作通过胆碱受体介导的疾病的预防和/或治疗剂,具有减少副作用或不良反应。
  • Pyrazole derivatives as jak inhibitors
    申请人:Almirall, S.A.
    公开号:EP2360158A1
    公开(公告)日:2011-08-24
    New pyrazole derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).
    新的吡唑衍生物具有化学结构式(I),公开了它们的制备方法,包括它们的制药组合物以及它们作为Janus激酶(JAK)抑制剂在治疗中的用途。
查看更多